APA
Martín Carrasco, Clara & Delgado Bonet, Pablo & Tomeo Martín, Beatriz Davinia & Pastor, Josep & de la Riva, Claudia & Palau Concejo, Paula & del Castillo Magan, Noemi & García Castro, Javier & Perisé Barrios, Ana Judith .Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.
ISO 690
Martín Carrasco, Clara & Delgado Bonet, Pablo & Tomeo Martín, Beatriz Davinia & Pastor, Josep & de la Riva, Claudia & Palau Concejo, Paula & del Castillo Magan, Noemi & García Castro, Javier & Perisé Barrios, Ana Judith. Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients.
https://hdl.handle.net/20.500.12080/32720
dc.contributor.author |
Martín Carrasco, Clara |
|
dc.contributor.author |
Delgado Bonet, Pablo |
|
dc.contributor.author |
Tomeo Martín, Beatriz Davinia |
|
dc.contributor.author |
Pastor, Josep |
|
dc.contributor.author |
de la Riva, Claudia |
|
dc.contributor.author |
Palau Concejo, Paula |
|
dc.contributor.author |
del Castillo Magan, Noemi
|
|
dc.contributor.author |
García Castro, Javier
|
|
dc.contributor.author |
Perisé Barrios, Ana Judith |
|
dc.date.accessioned |
2022-10-19T12:57:32Z |
|
dc.date.available |
2022-10-19T12:57:32Z |
|
dc.date.created |
2022-06-28 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12080/32720 |
|
dc.description.abstract |
: The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce
antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment¿s
safety, a blood count, biochemistry, and coagulation test were performed before treatment and during
follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were
also determined. The immune infiltration, vascularization, and viral presence in the tumor were
determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained
a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The
Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a
partial response and the rest showed stable disease at various times during the study. ICOCAV15 was
detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients.
Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we
suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment
of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results.
Keywords: oncolytic virus; virotherapy; immunotherapy; ICOCAV15; canine carcinoma |
es_ES |
dc.format |
application/pdf |
es_ES |
dc.language |
eng |
es_ES |
dc.rights |
CC-BY |
es_ES |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/deed.es |
es_ES |
dc.title |
Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients |
es_ES |
dc.type |
info:eu-repo/semantics/article |
es_ES |
dc.rights.accessrights |
info:eu-repo/semantics/openAccess |
es_ES |
dc.identifier.location |
N/A |
es_ES |